GGG. R. Gimatdinova

G. R. Gimatdinova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


G. R. Gimatdinova has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic polymorphisms in the development of anthracycline-induced cardiovascular toxicity in patients with follicular lymphoma

    by G. R. Gimatdinova, O. E. Danilova, Y. N. Milyutkina, A. S. Sustretov, P. V. Ilyasov, I. L. Davydkin, Г. Р. Гиматдинова, О. Е. Данилова, Ю. С. Милюткина, А. С. Сустретов, et al.

    Aim . To identify genetic variants associated with the risk of developing anthracycline-induced cardiovascular toxicity during antitumor therapy in patients with follicular lymphoma. Material and methods. The prospective study included 83 patients diagnosed with non-Hodgkin B-cell follicular lymphoma who received chemotherapy. Based on the results of follow-up standard and speckle-tracking echocardiography, the patients were divided into 2 groups: Group 1 — median age 59.0 (51.5; 69.0) years old, of which 44.1% were men (n=15), Group 2 — median age 55.0 (47.0; 66.5) years old, of which 55.1% were men (n=27)). Clinical, demographic, and laboratory assessments were performed, including high-throughput sequencing. Results . Minor alleles of rs2072708, rs2072710, rs2075939 NCF4, rs1443638, rs2306422, rs72547284, rs11661275 CELF4, CYBA, and FHOD3; rs246232 ABCC1; rs3749442 ABCC5 are associated with an increased risk of anthracycline-induced cardiovascular toxicity. Minor alleles of rs2233260, rs3833910, rs7232329, rs8096379, rs200571909, rs625223, rs2566514 MYL2, MYOM1, NEB and NOS3; rs1128503, rs2032582, rs2214102, rs2235013, rs2235033, rs4728699 ABCB1; rs212088, rs35604 ABCC1; rs1056892 and rs2835286 CBR3; rs1549758 NOS3, rs3731750 TTN is associated with a reducedlikelihood of complications. Conclusion . This study identified several novel genetic variants associated with the risk of cardiovascular toxicity, highlighting the potential for developing personalised approaches to anticancer therapy.

  • Open Access

    Optimization of the diagnosis of cardiovascular adverse events in patients with non-Hodgkin lymphomas

    by G. R. Gimatdinova, O. E. Danilova, O. A. Rubanenko, A. V. Kontsevaya, I. L. Davydkin, D. D. Tsyrenov

    Aim.  To identify the optimal combination of cardiovascular toxicity (CVT) markers for subsequent optimization of the diagnosis of cardiovascular adverse events in patients with non-Hodgkin lymphomas. Material and methods.  This prospective study was conducted to monitor cardiovascular adverse events in patients treated with the R-CHOP regimen. A total of 116 patients were divided into main (n=58, mean age 55,4±12,4 years, 25 (43,1%) men) and control groups (n=58, mean age 54,9±11,4 years, 32 (55,1%) men). Division of patients into subgroups was carried out taking into account CVT: A1 and B1 — with CVT: A1 — 21 patients, 55,9±11,17 years, 15 men (71,4%); B1 — 10 patients, 56,75±9,11 years, 6 men (60%); A2 — 37 patients, 55,16±13,12 years, 13 men (35,1%); B2 — 48 patients, mean age 54,24±12,18 years, men n=28 (58,3%). Results.  CVT was more common in men (p=0,039, p A1-A2 =0,008, p A2-B2 =0,031) and smokers (p=0,026, p A1-A2 =0,04, p A2-B2 =0,046, p A2-B1 =0,004). The level of N-terminal pro-brain natriuretic peptide (NT-proBNP) significantly increased from 86,50 (68,50;113,50) to 150,50 (71,00;372,50) pg/ml (p=0,023, p V2-V3 =0,026) in the target group of patients. Among patients with CVT, a longer QTc was recorded, as well as a lower level of global longitudinal systolic strain (p=0,008, Visit 2, p=0,003, Visit 3). Conclusion.  The mathematical model developed by the authors, based on paraclinical parameters and allowing for CVT diagnosis optimization, is proposed for use in real-world practice.

  • Biomarkers for Monitoring R-CHOP-associated Cardiotoxicity in Patients with Non-hodgkin Lymphoma

    by G.R. Gimatdinova, O.E. Danilova, I.L. Davydkin

    Introduction: Antineoplastic therapy may exert toxic effects on multiple organ systems in patients with hematologic malignancies. This is particularly relevant for individuals with indolent non-Hodgkin lymphoma treated with anthracycline-containing regimens, which carry a well-documented risk of cardiotoxicity. Materials and Methods: A case–control study was conducted at medical institutions in Samara, Russia, enrolling 72 patients diagnosed with grade 1–2 follicular B-cell non-Hodgkin lymphoma. All participants were administered six cycles of R-CHOP immunochemotherapy as clinically indicated. The primary objective was to identify early biomarkers of treatment-related cardiotoxicity. Results: The study identified three parameters as the most sensitive indicators of cardiovascular toxicity: prolongation of the corrected QT interval (QTc), reduction in left ventricular global longitudinal strain, and elevation of N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) levels. Additionally, the authors propose prognostic models to predict the presence of cardiotoxicity at 3 and 6 months of treatment. Discussion: Comparison of the study’s findings with previously published data revealed full consistency with the existing medical literature and further substantiates the authors' assertion regarding the prognostic utility of the identified laboratory and instrumental markers in the early detection of cardiotoxicity. Conclusion: Incorporating these biomarkers into routine cardiovascular monitoring protocols facilitates early detection of cardiotoxicity in patients with hematologic malignancies, enabling timely therapeutic adjustments and optimizing clinical management.

  • Open Access

    Markers Determining the Risk of Cardiovascular Toxicity Against the Background of Antitumor Immunochemotherapy

    by R. F. Gimranova, G. R. Gimatdinova, O. E. Danilova, I. L. Davydkin, O. A. Rubanenko

    Introduction. Malignant neoplasms occupy a leading place among the causes of death in the population. Despite the fact that antitumor treatment can significantly prolong the life of cancer patients, it continues to have a toxic effect on organs and systems. Patients with non-Hodgkin’s lymphoma of the indolent type receiving anthracycline-containing therapy regimens, which are the leading treatment regimens due to their availability from the pharmacological and financial side in the Russian Federation, are no exception. The purpose of the study. To identify clinical, laboratory and instrumental indicators, assessed after 3 months of treatment, determining the risk of developing cardiovascular toxicity against the background of 6-month antitumor immunochemotherapy according to the R-CHOP scheme in patients with indolent type of non-Hodgkin’s lymphomas. Materials and methods. An observational case-control study was conducted on the bases of medical institutions in Samara for patients diagnosed with B-cell follicular lymphoma, who were shown to undergo 6 courses of immunochemotherapy in the R-CHOP mode. The patients were divided into two groups: the main group n=21 (16 (76.2 %) men, average age 55.2(9.8) years) with verified cardiovascular toxicity and the control group n=51 (21 (41.2 %) men, average age 53.7(13.6) years) without her. During treatment, the targets were evaluated in two stages: at the start and after three courses of therapy. Results. At the start of the study, patients with verified cardiovascular toxicity had higher values of BMI, CDR, CDR, CDR, volume of the left and right atria, and distal diameter of the excretory tract compared with the control group (p < 0.05). Also, in patients with cardiovascular toxicity, the QTc significantly prolonged during treatment from 360 (245.0; 411.0) to 412 (279.0; 450.0) msec., p=0.032; the concentration of NTproBNP increased from 77 (67.0; 109.0) to 110 (75.0; 222.0) mg/ml, p=0.032; and the value of GLS LV decreased from -21.1 (19.7; 22.4) to -17.7 (15.1; 21.0)%, p=0.004. Conclusion. The expansion of diagnostic protocols within the framework of cardiovascular toxicity among patients with B-cell follicular lymphoma allows timely optimization of management tactics for patients with oncohematological profile.

  • Open Access

    Genetic predictors of cardiovascular toxicity in oncohematological patients

    by G. R. Gimatdinova, O. E. Danilova, I. L. Davydkin, Yu. S. Milyutkina, A. S. Sustretov, O. A. Germanova

    Aim. To identify single nucleotide polymorphisms reliably associated with cardiovascular toxicity in oncohematological patients receiving antitumor immunochemotherapy.Material and methods. For the study, 34 patients with an established diagnosis of non-Hodgkin's B-cell follicular lymphoma were prospectively selected at the Clinic of the Samara State Medical University, who were indicated for antitumor immunochemotherapy according to the R-CHOP protocol. During the follow-up, the patients were divided into 2 following groups: the main group consisted of 12 patients with cardiovascular toxicity (mean age, 42,4 (2,8) years, including men — n=3 (25%)), the control group — 22 patients without cardiovascular toxicity (mean age, 39,8 (1,7), including men — n=8 (36%)). Cardiovascular toxicity was verified on the basis of a combination of specific cardiological complaints with a decrease in the left ventricular ejection fraction >10% from the baseline or in absolute terms less than 53% and/or a decrease in the left ventricular longitudinal systolic strain >12% from the baseline and/or an increase in NT-proBNP >125 pg/ml.Results. The study presents the identified genetic features in oncohematological patients in the context of cardiovascular toxicity. ABCC5 rs1879257, PRKAG2 rs13224758, RYR2 rs10925391 and SLC22A7 rs414917 variants had a significant association with an increased risk of cardiovascular toxicity in the target group of patients by 5-6 times. In addition, the ABCB1 rs2032582 variant showed the opposite effect and was associated with a reduced risk of cardiovascular complications, having a protective effect on the cardiovascular system.Conclusion. Although further studies are needed to confirm the diagnostic and prognostic significance of the detected genetic variants, the study results indicate the prospects of genetic screening before antitumor immunochemotherapy as a future tool for stratifying oncohematological patients and minimizing cardiovascular toxicity.

  • Open Access

    Assessment of Clinical and Diagnostic Indicators of Cardiovascular Toxicity in Patients with Non-Hodgkin’s Lymphomas in the Course of Programmatic Antitumor Therapy

    by G. R. Gimatdinova, O. E. Danilova, I. L. Davydkin, O. A. Rubanenko, T. Y. Stepanova

    Цель исследования. Изучить ассоциацию клинико-диагностических показателей кардиоваскулярной токсичности у пациентов с неходжкинскими лимфомами, находящихся в процессе программной противоопухолевой иммунохимиотерапии.Материалы и методы. Проспективно было отобрано 72 пациента с подтвержденным диагнозом «индолентная неходжкинская лимфома», которым показано проведение противоопухолевого лечения по схеме R-CHOP. Пациенты были обследованы в два визита: V1 — на старте и V2 — после 6 курсов терапии. В процессе наблюдения пациенты были поделены на 2 группы: основную — с признаками сердечно-сосудистой токсичности (21 пациент, 16 (76,2 %) мужчин, средний возраст 55,2 (9,8) лет) и контрольную — без нее (51 пациент, 21 (41,2 %) мужчин, средний возраст 53,7(13,6) лет. Кардиоваскулярная токсичность верифицировалась на основании сочетания жалоб с изменениями в сократительной способности миокарда: снижения фракции выброса левого желудочка >10 % от исходного уровня или в абсолютном выражении менее, чем 53 % и/или снижения продольной систолической деформации левого желудочка >12 % от исходного уровня.Результаты. По окончанию основного лечения в обеих группах наблюдения отмечено статистически значимое увеличение QTc. Значимо менялось значение глобальной продольной систолической деформации левого желудочка у пациентов основной группы при одномоментном отсутствии ключевых сдвигов в отношении фракции выброса левого желудочка. Наиболее чувствительным лабораторным показателем кардиоваскулярной токсичности оказался NTproBNP, концентрация которого статистически значимо увеличивалась у основной группы пациентов.Заключение. Расширение минимальной диагностической панели и комплексный подход к верификации кардиоваскулярной токсичности у пациентов онкогематологического профиля, получающих потенциально токсичную для сердечно-сосудистой системы терапию, позволит существенно улучшить показатели эффективности работы ключевых служб здравоохранения, снизить финансовые расходы на нивелирование осложнений и повысить качество жизни пациентов.


  • Open Access

    Oral anticoagulants or antiplatelet drugs after heart valve reconstructive surgery: modern guidelines for the practitioners

    by В. П. Кузьмин, A. A. Gevorgyan, G. R. Gimatdinova, O. E. Danilova, I. L. Davydkin, S. P. Krivova, R. K. Khairetdinov, G. I. Davydkin

    After heart valve surgery, anticoagulant therapy is usually recommended. The duration and necessity of combining oral anticoagulants with antiplatelet drugs depends on the type of manipulation performed, patient comorbidity and some other factors. Several randomized trials have shown that continued direct oral anticoagulation as monotherapy in some groups of patients requiring cardiac surgery is superior in efficacy and safety to treatment combining anticoagulant and antiplatelet drugs. The presented literature review reflects the management strategy of patients after heart valve operations.

  • Open Access

    Diagnostic capabilities of instrumental methods for studying early cardiovascular adverse events in patients with lymphoproliferative disorders, quality and safety issues

    by G. R. Gimatdinova, O. E. Danilova, I. L. Davydkin, U. L. Dzhulakyan, E. V. Usenko

    Aim. To study the possibilities of instrumental research methods in relation to the earliest detection of cardiovascular events in oncohematological patients receiving antitumor immunochemotherapy, as well as to deter­mine the requirements for documenting adverse events.Material and methods. For the study, 63 patients were prospectively selected with a diagnosis of indolent non-Hodgkin lymphoma, who were indicated for antitumor immunochemotherapy. The patients were examined in three stages (before treatment, after 3 and 6 cycles of therapy) and divided into 2 groups by simple randomization. Cardiovascular toxicity in the main group of patients was assessed using 3D transthoracic echocardiography, analysis of left ventricular (LV) global longitudinal systolic strain and electrocardiography. The control group underwent a standard 3D echocardiography with analysis of LV ejection fraction. Clinical manifestations of cardiovascular events were assessed in all patients during treatment.Results. According to the study, significant changes were obtained in LV ejection fraction on the third visit — a decrease from 58,9±1,07 to 48,1±0,73% (pConclusion. The long period of latent cardiovascular toxicity emphasizes the need for early verification of cardiovascular complications of antitumor therapy and expansion of the established paraclinical diagnostic minimum. In addition, taking into account the accumulated experience, recommendations are presented for the preparation of medical documentation in order to ensure the safety and quality of care.


  • Open Access

    Genetic polymorphisms associated with the development of arrhythmic type of cardiovascular events

    by G. R. Gimatdinova, O. E. Danilova, I. L. Davydkin, R. K. Khairetdinov, A. V. Antipova

    The review analyzes the global agenda on mutational status of genes associated with adverse cardiovascular events of arrhythmic type. Whole exome sequencing will identify a risk group for the likelihood of early or delayed cardiovascular events of arrhythmic type, especially among patients receiving anticancer therapy with cardiotoxic drugs. The dedicated up-to-date panel of genetic polymorphisms will provide an opportunity to optimize management of patients, based on not only clinical, paraclinical and anamnestic data.


  • Open Access

    Hypertensive patients features of the microcirculation type after new coronavirus infection of COVID-19

    by I. A. Zolotovskaya, G. R. Gimatdinova, I. L. Davydkin

    Introduction. The COVID-19 pandemic multiplies the incidence of long-term adverse events. Family history of heart disease predicates the necessity of study hemostasis in hypertensive patients. The purpose was to study the microcirculation in hypertensive COVID-19 survivors. Materials and methods. We selected patients treated at the hospitals of Samara from January to March 2021. COVID-19 survivors (diagnosis was confirmed by polymerase chain reaction analysis) were divided into 2 groups and analysed: the group with family history of hypertension (167 patients) and control group with no relevant past medical history (68 patients). The main microcirculation characteristics were evaluated by laser Doppler flowmetry of skin blood flow. Results. The average age of COVID-19 survivors was 52.3±14.2 years, n=86 (51.4 %) – male. The majority of patients (n=61/36.5 %) were 45 to 54 years. A fifth of the patients (n=35/20.9 %) showed no complaints about the underlying disease, the clinical manifestations of the rest were general weakness, fever, shortness of breath, cough, headaches, unstable blood pressure, inflammation of the ENT organs. By comparison the microcirculation parameters of the case patients and control group, a decreased perfusion was detected. It requires a preventive medicine to prevent from early and distant micro and macrothrombosis. Conclusion. The study of microcirculation essential features by the LDF of skin blood flow revealed a pathological type with a predominance of vasoconstrictions in patients with a history of hypertension. Taking into account the proven increase in the incidence of thrombotic events in COVID-19 survivors, the noticed changes in microcirculation require a new approach to prevent from adverse events concerning the hypercoagulation process, especially in patients with famil y history of heart disease.